Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN 株式レポート

時価総額:US$1.7b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Supernus Pharmaceuticals マネジメント

マネジメント 基準チェック /24

Supernus Pharmaceuticals'の CEO はJack Khattarで、 Jan2005年に任命され、 の在任期間は 19.42年です。 の年間総報酬は$ 13.28Mで、 7.3%給与と92.7%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の3.52%を直接所有しており、その価値は$ 50.36M 。経営陣と取締役会の平均在任期間はそれぞれ9.2年と14.4年です。

主要情報

Jack Khattar

最高経営責任者

US$13.3m

報酬総額

CEO給与比率7.3%
CEO在任期間19.7yrs
CEOの所有権3.5%
経営陣の平均在職期間9.4yrs
取締役会の平均在任期間14.7yrs

経営陣の近況

Recent updates

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02
Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Nov 30
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Oct 19
Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

CEO報酬分析

Supernus Pharmaceuticals の収益と比較して、Jack Khattar の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

US$5m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$13mUS$963k

US$1m

Sep 30 2023n/an/a

US$26m

Jun 30 2023n/an/a

US$43m

Mar 31 2023n/an/a

US$52m

Dec 31 2022US$10mUS$914k

US$61m

Sep 30 2022n/an/a

US$38m

Jun 30 2022n/an/a

US$57m

Mar 31 2022n/an/a

US$73m

Dec 31 2021US$8mUS$870k

US$53m

Sep 30 2021n/an/a

US$82m

Jun 30 2021n/an/a

US$100m

Mar 31 2021n/an/a

US$111m

Dec 31 2020US$7mUS$836k

US$127m

Sep 30 2020n/an/a

US$129m

Jun 30 2020n/an/a

US$118m

Mar 31 2020n/an/a

US$116m

Dec 31 2019US$8mUS$812k

US$113m

Sep 30 2019n/an/a

US$106m

Jun 30 2019n/an/a

US$105m

Mar 31 2019n/an/a

US$103m

Dec 31 2018US$7mUS$724k

US$111m

Sep 30 2018n/an/a

US$99m

Jun 30 2018n/an/a

US$87m

Mar 31 2018n/an/a

US$73m

Dec 31 2017US$6mUS$614k

US$57m

報酬と市場: Jackの 総報酬 ($USD 13.28M ) は、 US市場 ($USD 5.66M ) の同規模の企業の平均を上回っています。

報酬と収益: Jackの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。


CEO(最高経営責任者

Jack Khattar (63 yo)

19.7yrs

在職期間

US$13,278,093

報酬

Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jack Khattar
Founder19.7yrsUS$13.28m3.54%
$ 60.0m
Timothy Dec
Senior VP & CFO3.1yrsUS$2.38m0.013%
$ 221.3k
Padmanabh Bhatt
Chief Scientific Officer & Senior VP of Intellectual Property12.5yrsUS$1.47m0.018%
$ 297.7k
Frank Mottola
Senior Vice President of Quality4.7yrsUS$1.79m0.014%
$ 239.4k
Jonathan Rubin
Senior VP of Research & Development and Chief Medical Officer4.6yrsUS$1.59m0.0084%
$ 142.8k
Kevin Anderson
Compliance Officer12.7yrsデータなしデータなし
Todd Horich
Senior Vice President of Marketing9.7yrsデータなしデータなし
Taylor Raiford
Senior Vice President of Sales9.7yrsデータなしデータなし
Bryan Roecklein
Senior Vice President of Corporate Development9.2yrsデータなしデータなし
Jeff Bozick
Senior Vice President of Supply Chain3.3yrsデータなしデータなし

9.4yrs

平均在職期間

63yo

平均年齢

経験豊富な経営陣: SUPNの経営陣は経験豊富で経験豊富です(平均在職期間は9.2年)。


取締役

名称ポジション在職期間報酬所有権
Jack Khattar
Founder19.7yrsUS$13.28m3.54%
$ 60.0m
Charles Newhall
Independent Chairman of the Board19.7yrsUS$407.02k0.22%
$ 3.7m
Georges Gemayel
Independent Director9.5yrsUS$378.52k0.024%
$ 409.7k
Carrolee Barlow
Independent Director6.3yrsUS$376.02k0.031%
$ 529.2k
Frederick Hudson
Independent Director14.7yrsUS$385.02k0.067%
$ 1.1m

14.7yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: SUPNの 取締役会 は経験豊富で 経験豊富 です ( 14.4年の平均在任期間)。